ZNF521

ZNF521 is a multi-zinc-finger nuclear transcription co-factor that controls the differentiation state of hematopoietic and mesenchymal progenitors by partnering with sequence-specific transcription factors and chromatin-modifying complexes (PMID:14630787, PMID:25774781). In BMP signaling it complexes with SMAD1 and SMAD4 to bind a BMP2/4-responsive element and enhance BMP-driven transcription, while through its terminal six zinc fingers it inhibits the B-cell determinant EBF1, thereby restraining B-lymphoid differentiation (PMID:14630787, PMID:15580294). ZNF521 associates with the NuRD chromatin-remodeling/deacetylase complex via an N-terminal motif, and this NuRD-binding motif is required for its cooperative enhancement of GLI1/GLI2-driven Hedgehog transcription (PMID:25774781, PMID:31558698); consistent with a deacetylase-coupled mechanism, ZNF521 also binds HDAC8 to lower SMC3 acetylation and sustain leukemic proliferation (PMID:39309877). In leukemogenesis ZNF521 acts as an oncogenic effector: it cooperates with E2A-HLF to drive B-lineage ALL, and its promoter is directly bound and activated by MLL-AF9/MLL-ENL fusions to maintain a myeloid differentiation block, such that its loss triggers cell-cycle arrest and myeloid maturation (PMID:20062079, PMID:28412732, PMID:39309877). Beyond blood, ZNF521 represses both adipogenic and osteoblastic differentiation of mesenchymal stem cells, partly through suppression of EBF1 and ZNF423 (PMID:29938352, PMID:30567301).

1. 2002 Medium

   Established that the ZNF521 protein (Evi3/EHZF) is nuclear and links BMP signaling to B-cell regulation, framing it as a candidate SMAD-associated factor.

   Evidence Nuclear localization, RT-PCR expression in B cells, and Co-IP of SMAD1/SMAD4 in mouse ortholog

   PMID:12393497

   Open questions at the time

   • EBF interaction inferred by homology, not directly shown
   • No domain mapping of SMAD interaction
2. 2003 Medium

   Defined ZNF521's dual transcriptional role: it potentiates BMP/SMAD-responsive transcription while inhibiting EBF1, positioning it at a node controlling B-lymphoid commitment.

   Evidence Co-IP of SMAD1/4, BMP2/4-responsive reporter assays, and EBF transactivation assays in human cells

   PMID:14630787

   Open questions at the time

   • Direct DNA binding by ZNF521 not demonstrated
   • Mechanism of EBF1 inhibition undefined
3. 2005 Medium

   Localized the EBF-modulating activity to the terminal six zinc fingers and connected it to a B-cell oncogenic output.

   Evidence Domain-deletion transactivation assays and primary leukemia cell reconstitution with surface marker analysis (mouse ortholog)

   PMID:15580294

   Open questions at the time

   • No structural basis for zinc-finger/EBF contact
   • Single ortholog system
4. 2010 High

   Demonstrated in vivo oncogenic cooperation, showing ZNF521 overexpression collaborates with E2A-HLF to specifically drive B-lineage ALL.

   Evidence Retroviral insertional mutagenesis, inducible knock-in and transgenic mouse models

   PMID:20062079

   Open questions at the time

   • Molecular mechanism of cooperation with E2A-HLF not resolved
   • Target genes downstream of the block not mapped
5. 2014 Low

   Extended ZNF521 function to non-hematopoietic differentiation by implicating it in chondrocyte phenotype maintenance.

   Evidence RNAi silencing in primary chondrocytes with COL2A1/COL1A1 ratio readout

   PMID:24976683

   Open questions at the time

   • Single-method knockdown with no mechanistic pathway placement
   • No direct target identified
6. 2015 Medium

   Defined the chromatin machinery ZNF521 operates through by identifying NuRD core components, ZNF423, Spt16, and Spt5 as physical partners.

   Evidence Cross-linking Co-IP with shotgun proteomics and Western blot validation

   PMID:25774781

   Open questions at the time

   • Interaction interfaces not mapped
   • Functional consequence of each partner not tested here
7. 2017 High

   Placed ZNF521 downstream of MLL fusion oncoproteins, showing it is a direct transcriptional target sustaining the AML differentiation block.

   Evidence ChIP of MLL-AF9/MLL-ENL at the ZNF521 promoter, shRNA knockdown with proliferation/colony/differentiation and expression profiling

   PMID:28412732

   Open questions at the time

   • Direct downstream targets of ZNF521 in AML not defined
   • Co-factor dependence of the block not dissected
8. 2018 Medium

   Established ZNF521 as a brake on mesenchymal differentiation along both adipogenic and osteogenic lineages, acting via EBF1 and ZNF423 repression.

   Evidence Reciprocal lentiviral overexpression and RNAi in hADSCs with differentiation assays and marker quantification

   PMID:29938352 PMID:30567301

   Open questions at the time

   • Direct vs indirect repression of EBF1/ZNF423 not separated
   • Chromatin occupancy at these loci not shown
9. 2019 High

   Connected ZNF521 to Hedgehog signaling and mechanistically tied its co-activator function to NuRD recruitment.

   Evidence Reciprocal Co-IP with GLI1/GLI2, GLI-responsive luciferase reporters, N-terminal motif deletion, and HDAC/GLI pharmacological inhibition

   PMID:31558698

   Open questions at the time

   • How NuRD recruitment activates rather than represses GLI targets unresolved
   • No genome-wide GLI/ZNF521 co-occupancy
10. 2020 Low

    Reported a context-dependent tumor-suppressive role in hepatocellular carcinoma via Runx2 repression and AKT inactivation.

    Evidence ZNF521 overexpression/silencing in HCC cells with proliferation/colony assays and Western blot for Runx2 and pAKT

    PMID:32913476

    Open questions at the time

    • No ChIP or direct Runx2 binding evidence
    • Link between Runx2 and AKT pathway not mechanistically established
11. 2022 Medium

    Defined a ZNF521→EBF1→AKR1B1 axis explaining how ZNF521 promotes gastric cancer progression.

    Evidence shRNA knockdown, luciferase reporter and ChIP for EBF1-AKR1B1 promoter, with migration/invasion assays

    PMID:36397644

    Open questions at the time

    • Direct ZNF521 binding at EBF1 not shown
    • Generality of axis beyond gastric cancer untested
12. 2024 Medium

    Identified an HDAC8/SMC3 deacetylation mechanism by which ZNF521 drives leukemic proliferation.

    Evidence Co-IP of ZNF521-HDAC8, shRNA knockdown, HDAC8 inhibition, SMC3 acetylation Western blots, cell cycle and apoptosis assays

    PMID:39309877

    Open questions at the time

    • Whether ZNF521 recruits HDAC8 to specific loci unknown
    • Direct vs indirect control of CDK2/CDK6 unresolved
13. 2025 Low

    Implicated ZNF521 in early neural morphogenesis as a negative regulator of ectopic neural tube closure.

    Evidence Arrayed CRISPRi screen in hPSC-derived anterior neurulation organoids with single-cell transcriptomics (preprint)

    PMID:bio_10.1101_2025.07.21.665862

    Open questions at the time

    • Preprint, no biochemical mechanism
    • Relationship to ZIC2/SOX11 program correlative

• How ZNF521 toggles between co-activation (BMP/SMAD, GLI) and repression (EBF1, ZNF423, Runx2), and whether this reflects locus-specific recruitment of NuRD/HDAC versus distinct partner sets, remains unresolved.
• No genome-wide DNA-binding/occupancy map
• Determinants of activator vs repressor mode unknown
• No structural model of zinc-finger/partner contacts